Search hospitals > Pennsylvania > York
UPMC Memorial
Claim this profileYork, Pennsylvania 17408
Global Leader in Breast Cancer
Global Leader in Lung Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Squamous Cell Carcinoma
47 reported clinical trials
20 medical researchers
Summary
UPMC Memorial is a medical facility located in York, Pennsylvania. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma and other specialties. UPMC Memorial is involved with conducting 47 clinical trials across 87 conditions. There are 20 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Dan P. Zandberg, and Anuradha Krishnamurthy.Area of expertise
1Breast Cancer
Global LeaderHER2 positive
ER positive
Stage II
2Lung Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
Liza C. VillaruzUniversity of Pittsburgh Cancer Institute (UPCI)6 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
40 reported clinical trials
59 drugs studied
Adam Brufsky, MDUniversity of Pittsburgh Cancer Institute (UPCI)2 years of reported clinical research
Expert in Breast Cancer
Expert in Breast cancer
31 reported clinical trials
70 drugs studied
Dan P. ZandbergUniversity of Pittsburgh Cancer Institute (UPCI)4 years of reported clinical research
Expert in Squamous Cell Carcinoma
Studies Head and Neck Squamous Cell Carcinoma
20 reported clinical trials
36 drugs studied
Anuradha KrishnamurthyUniversity of Pittsburgh Cancer Institute (UPCI)6 years of reported clinical research
Studies Colorectal Cancer
Studies Cancer
18 reported clinical trials
32 drugs studied
Clinical Trials running at UPMC Memorial
Lung Cancer
Prostate Cancer
Small Cell Lung Cancer
Breast Cancer
Oral Cancers
Prostate Adenocarcinoma
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Oropharyngeal Carcinoma
Laryngeal Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Stereotactic Radiosurgery vs Whole-Brain Radiotherapy
for Brain Metastasis from Lung Cancer
This phase III trial compares the effect of stereotactic radiosurgery to standard of care memantine and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue. Whole brain radiation therapy delivers a low dose of radiation to the entire brain including the normal brain tissue. Hippocampal avoidance during whole-brain radiation therapy (HA-WBRT) decreases the amount of radiation that is delivered to the hippocampus which is a brain structure that is important for memory. The drug, memantine, is also often given with whole brain radiotherapy because it may decrease the risk of side effects related to thinking and memory. Stereotactic radiosurgery may decrease side effects related to memory and thinking compared to standard of care HA-WBRT plus memantine.
Recruiting2 awards Phase 315 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at UPMC Memorial?
UPMC Memorial is a medical facility located in York, Pennsylvania. This center is recognized for care of Breast Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma and other specialties. UPMC Memorial is involved with conducting 47 clinical trials across 87 conditions. There are 20 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Dan P. Zandberg, and Anuradha Krishnamurthy.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.